Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Usman, Tariq Jamal Siddiqi, Stefan D. Anker, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 25, pp. 2377-2387
Closed Access | Times Cited: 69

Showing 26-50 of 69 citing articles:

Sodium–Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension
Yilan Hu, Jiaqi Bao, Zhicheng Gao, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 407-415
Open Access | Times Cited: 3
Are We Ready for Expanding the Use of Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Acute Myocardial Infarction?
Paschalis Karakasis, Dimitrios Patoulias, George Giannakoulas, et al.
Journal of Cardiovascular Pharmacology (2024) Vol. 84, Iss. 1, pp. 26-28
Open Access | Times Cited: 3
Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction
Chen Gao, Zhaojun Xiong, Yunxia Liu, et al.
Circulation Research (2024) Vol. 135, Iss. 5, pp. 614-628
Open Access | Times Cited: 3
Impact of Sodium-glucose Cotransporter 2 Inhibitor on Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure
Zixu Zhao, Yiping Wang, Chao Jiang, et al.
Heart Rhythm (2024)
Closed Access | Times Cited: 3
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
Mikhail Kosiborod, Sheryl L. Windsor, Orly Vardeny, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 10, pp. 725-734
Closed Access | Times Cited: 3
Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Failure to improve cardiac remodelling and outcomes post‐myocardial infarction: Insights from EMPRESS‐MI
Francesco Fioretti, Gregg W. Stone, Javed Butler
European Journal of Heart Failure (2025)
Open Access
Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials
Syeda Ayesha Shah, Hasan Mushahid, Ali Salman, et al.
Drugs & Aging (2025)
Closed Access
Ketone Bodies in Renal Function and Diabetic Kidney Disease
Hamza Mechchate
The Journal of Nutritional Biochemistry (2025), pp. 109915-109915
Closed Access
Effects of diabetes mellitus and glycemic traits on cardiovascular morpho-functional phenotypes
Zhaoyue Li, Jie Xiong, Yutong Guo, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes
Sahib Singh, Aakash Garg, Udaya S. Tantry, et al.
The American Journal of Cardiology (2024) Vol. 218, pp. 24-31
Closed Access | Times Cited: 1
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Acute Coronary Syndrome
Jiawei Song, Yan Liu, Yani Xu, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 6, pp. 1847-1855
Open Access | Times Cited: 1
Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis
Hsiao‐Huai Kuo, Kuang-Te Wang, Hsin-Hao Chen, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Digital Preoperative Huddle Platform Use Leads to Decreased Surgical Cost
Alexander Eremiev, Dennis London, Roee Ber, et al.
Neurosurgery (2024) Vol. 95, Iss. 5, pp. 1178-1185
Closed Access | Times Cited: 1
Assessing the Effect of Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) on Outcomes in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis
Scott Nall, Anurag Rawat, Fahad Shaukat Gill, et al.
Cureus (2024)
Open Access | Times Cited: 1
The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis
Muhammad Usman, Arsalan Hamid, Shurjeel Uddin Qazi, et al.
Global Cardiology (2024) Vol. 2, Iss. 2
Closed Access | Times Cited: 1
Importance of weight reduction in type 2 diabetes for the prevention of CVD outcomes: A systematic review of CVOTs
Nebojša Lalić, Aleksandra Jotić, Ljiljana Lukić, et al.
Diabetes Research and Clinical Practice (2024) Vol. 216, pp. 111816-111816
Closed Access | Times Cited: 1
Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide
Subodh Verma, Francesco Cosentino, Mikhail Kosiborod
European Heart Journal (2024)
Open Access | Times Cited: 1
Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight
Shams Tarek Osman, Waziha Purba, Oluwatosin Daramola, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117771-117771
Open Access | Times Cited: 1
The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: A meta-analysis
Eric Pasqualotto, Farley Reis Rodrigues, Giovana Barros e Silva Ribeiro, et al.
Journal of Stroke and Cerebrovascular Diseases (2024) Vol. 33, Iss. 8, pp. 107730-107730
Closed Access | Times Cited: 1
Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Veera Ganesh Yerra, Kim A. Connelly
Physiology (2024) Vol. 39, Iss. 6, pp. 412-434
Closed Access | Times Cited: 1
Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?
Carlos A Gongora, Lili Zhang, Juan Lopez Mattei, et al.
Cardiovascular Drugs and Therapy (2024)
Closed Access | Times Cited: 1
Metabolic acidosis in patients with diabetes 2 undergoing cardiac surgery
Hege Kristin Brekke, Gunhild Holmaas, Marianne C. Astor, et al.
European Journal of Anaesthesiology (2024)
Closed Access | Times Cited: 1
Targeting the Gut-Heart Axis Improves Cardiac Remodeling in a Clinical Scale Model of Cardiometabolic Syndrome
Florence M. Herisson, Gaston Cluzel, Maria Antonia Llopis-Grimalt, et al.
JACC Basic to Translational Science (2024) Vol. 10, Iss. 1, pp. 1-15
Open Access | Times Cited: 1
SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death
Stephen D. Wiviott, David D. Berg
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 25, pp. 2388-2390
Open Access | Times Cited: 3

Scroll to top